Compare Shell PLC (SHEL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Travere Therapeutics Inc. Common Stock — how do they compare? Shell PLC trades at $103.86 (market cap $290.47B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Shell PLC is far larger — about 59.5× Travere Therapeutics Inc. Common Stock's market cap, and Shell PLC pays a 3.03% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 91 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SHEL | TVTX | |
|---|---|---|
Market Cap | $290.47B | $4.88B |
Volume | 4,901,394 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $103.58 | $67.52 |
52-Week Low | $70.31 | $26.79 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $332.17B | $5.01B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $103.58, up 1.96% today, near its consensus price target of $103.24. The stock shows bullish momentum with strong earnings beats in Q1 and Q2 2026, though Q4 2025 missed estimates. Recent news highlights expansion in LNG Canada Phase 2, doubling export capacity. Valuation metrics appear reasonable with a P/E of 11.39 and EV/EBITDA of 4.89. Operating cash flow remains robust at $42.86 billion for 2025, supporting dividend payments and strategic investments.
Outlook is positive with analyst consensus favoring Buy ratings (61.54%) and a high price target of $122.40. Key opportunities include LNG growth and portfolio optimization, while risks involve energy price volatility and execution of large-scale projects. The stock's current technical overbought condition may prompt near-term consolidation.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
